MAXCYTE 8-K: Officer/Director Changes & Comp Arrangements
Ticker: MXCT · Form: 8-K · Filed: Jan 26, 2024 · CIK: 1287098
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**MAXCYTE filed an 8-K about officer/director changes and compensation, watch for details.**
AI Summary
MAXCYTE, INC. filed an 8-K on January 26, 2024, reporting an event that occurred on January 23, 2024, related to changes in directors or officers and their compensation. This filing indicates potential shifts in leadership or executive pay structures, which could influence the company's strategic direction and financial performance. Investors should monitor subsequent filings for details on these changes, as they can impact future stock valuation and operational efficiency.
Why It Matters
Changes in executive leadership or compensation can signal new strategic directions or financial health, directly impacting investor confidence and the company's future performance.
Risk Assessment
Risk Level: medium — The filing indicates changes in leadership and compensation, which can introduce uncertainty regarding future company direction and stability until specific details are disclosed.
Analyst Insight
A smart investor would monitor MAXCYTE's subsequent filings and press releases for specific details on the reported officer/director changes and compensatory arrangements, as these will clarify the impact on company strategy and financial outlook.
Key Players & Entities
- MAXCYTE, INC. (company) — the registrant filing the 8-K
- January 23, 2024 (date) — date of the earliest event reported
- January 26, 2024 (date) — date the 8-K was filed
- 001-40674 (other) — Commission File Number for MaxCyte, Inc.
Forward-Looking Statements
- Further details regarding the specific individuals involved in the officer/director changes and the nature of their compensatory arrangements will be disclosed in subsequent filings or company announcements. (MAXCYTE, INC.) — high confidence, target: Q1 2024
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 23, 2024.
What specific items were reported under Item 5.02 of this 8-K?
Item 5.02 of this 8-K reported 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 26, 2024.
What is the business address of MaxCyte, Inc. as stated in the filing?
The business address of MaxCyte, Inc. is 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850.
What is the Commission File Number for MaxCyte, Inc. according to this filing?
The Commission File Number for MaxCyte, Inc. is 001-40674.
Filing Stats: 561 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-01-26 16:45:19
Key Financial Figures
- $0.01 — ge on which registered Common Stock, $0.01 par value MXCT The Nasdaq Stock Mar
Filing Documents
- mxct-20240123x8k.htm (8-K) — 40KB
- mxct-20240123xex10d1.htm (EX-10.1) — 102KB
- 0001558370-24-000593.txt ( ) — 283KB
- mxct-20240123.xsd (EX-101.SCH) — 3KB
- mxct-20240123_lab.xml (EX-101.LAB) — 16KB
- mxct-20240123_pre.xml (EX-101.PRE) — 10KB
- mxct-20240123x8k_htm.xml (XML) — 5KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 10.1 Severance Agreement, between the registrant and Cenk Sumen. 104 Cover Page Interactive Data (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: January 26, 2024 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer